Navigation Links
Cell Therapeutics to Report Third Quarter Financial Results after Market on October 30, 2013
Date:10/22/2013

SEATTLE, Oct. 23, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its third quarter financial results on Wednesday, October 30, 2013, after the close of the U.S. financial markets.  Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT).  Access to the event can be obtained as follows:

Wednesday, October 30, 2013
1:30 p.m. PDT/4:30 p.m. EDT/10:30 p.m. CEST
1-866-225- 8754 (domestic)
+1 480-629-9819 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI's website, www.celltherapeutics.com.  Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call.  Callers can access the replay by dialing 1-800-406-7325 (domestic) or +1 303-590-3030 (international).  The access code for the replay is 4647208.  The telephone replay will be available until Wednesday, November 6, 2013.

About Cell Therapeutics

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable.  CTI is headquartered in Seattle, WA.  For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Contacts:

Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014 Sanofi Pasteur, the ... SNY ), announced today that the first lots of Fluzone ... season have been released by the U.S. Food and Drug ... 21, 2014, representing the first of at least 65 million ... will be delivered to U.S. health care providers and pharmacies ...
(Date:7/22/2014)... Israel , July 22, 2014 Galmed ... clinical-stage biopharmaceutical company focused on the development and commercialization ... liver diseases and cholesterol gallstones, announced today that the ... Galmed,s Investigational New Drug, or IND, application.  Such clearance ... product candidate, aramchol, in the United States ...
(Date:7/22/2014)... -- Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: ... the Icahn School of Medicine at Mount ... to utilize its proprietary information and data package for ... Type C Disease (NPC), a rare disease, mostly of ... also covers other diseases and disorders relying on activation ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
... 2011 Techne Corporation,s (NASDAQ: TECH ) financial ... 30, 2011 include the following highlights: , ... per diluted share.  Earnings for the quarter grew 21.2% to ... intangible asset amortization, costs recognized upon the sale of inventory ...
... 2, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ... LEVADEX® orally inhaled migraine drug for the potential acute treatment ... the U.S. Food and Drug Administration (FDA), with a goal ... Fee Act (PDUFA). In accordance with the Company,s collaboration agreement ...
Cached Medicine Technology:Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 2Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 3Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 4Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 5Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 6Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 7Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 8Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 9Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 10Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 11MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® 2MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® 3MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® 4
(Date:7/22/2014)... (Boston)-- Researchers from Boston University School of Medicine ... that participants who received care through BMC,s Violence ... physical, mental, emotional and social needs of violently ... injuries and experienced life changing behaviors through connections ... feel trust and hope. These findings are reported ...
(Date:7/22/2014)... The European Bio stimulants Market report defines ... analysis and forecast of revenue. The bio stimulants market ... million in 2013 to $940.6 million by 2018, at ... Browse through the TOC of the Europe Bio stimulants ... analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes ...
(Date:7/22/2014)... California (PRWEB) July 22, 2014 In ... women in recovery, the Marinello School of Beauty joined ... Addiction Treatment Center for a free “Make-over Day.” ... to be of service to the community, and The ... and renewed. They also gained some first-hand experience about ...
(Date:7/22/2014)... 2014 Expert Publishing ... , announces the launch of PoisonEXPERT™ , ... safety professionals employed by organizations that use or ... manage the impact of chemicals on their employees ... relevant chemical-specific information and medical protocols that allows ...
(Date:7/22/2014)... Transparency Market Research has announced the ... Diagnostics Market – Global Industry Analysis, Size, Share, Growth, ... comprehensive database. This industry is considered as the most ... valued at USD 8.7 billion by 2019 and expected ... to 2019. Molecular diagnostics is the class of diagnostic ...
Breaking Medicine News(10 mins):Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 2Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 3Health News:PoisonEXPERT™ from ExPub Now Available 2Health News:PoisonEXPERT™ from ExPub Now Available 3Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 2Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 3Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 4
... a Diet High in Fruits and Vegetables ,Healthy Foods ... patients with kidney disease, the Western diet produces an acidic ... worsens with age as kidney function declines. Nimirit Goraya, MD ... and her colleagues conducted a study to see if consuming ...
... By Ellin Holohan HealthDay Reporter , FRIDAY, ... against alcohol use, can relax and have a drink a ... weight, two new Dutch studies show. The researchers found ... be unfounded, while concerns about weight are not. Both ...
... 19 (HealthDay News) -- A new, small study suggests that the ... dose of tamoxifen, a drug commonly used to prevent and treat ... cough medicine at about the same rate as tamoxifen, allowing doctors ... drug. "This study is starting to identify a personalized ...
... NEW YORK (Nov. 20, 2010) Columbia University Medical ... a Harvard researcher who has made important advances in ... and heart disease. A promising young investigator at Columbia ... the basis for disordered lipid metabolism in diabetes. ...
... By Madonna Behen HealthDay Reporter , FRIDAY, Nov. ... on U.S. college campuses, college officials are trying various ways ... targeted off-campus boozing shows some promise, researchers say. ... cut the level of heavy drinking at private parties and ...
... 19, 2010 University of Houston (UH) physicists are ... a crucial protein that, when malfunctioning, may cause Alzheimer,s ... physics at UH, and Antonios Samiotakis, a physics Ph.D. ... function, and folding of phosphoglycerate kinase (PGK) are strongly ...
Cached Medicine News:Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 2Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 3Health News:Moderate Drinking Could Lower Death Risk for Kidney Transplant Patients 2Health News:Moderate Drinking Could Lower Death Risk for Kidney Transplant Patients 3Health News:Moderate Drinking Could Lower Death Risk for Kidney Transplant Patients 4Health News:Cough Syrup Might Help With Dosing of Breast Cancer Drug 2Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 2Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 3Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 4Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 2Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 3Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 2Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 3